ESMO 2017: Docetaxel-based triplet therapy in gastric cancer: results from the FLOT4 trial confirm superiority over standard care

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • The superiority of docetaxel-based triplet pre-operative therapy (docetaxel., oxaliplatin, leucovorin, and 5-fluorouracil [FLOT regimen]) over standard care (epirubicin, cisplatin, and 5- fluorouracil or capecitabine [ECF/ECX regimen]) in patients with resectable gastric cancer has...